Evidence map›Paper›PMID 20979472›Full record

ArticleThe New England journal of medicine2010

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

James E Butrynski, David R D'Adamo, Jason L Hornick, Paola Dal Cin, Cristina R Antonescu, Suresh C Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J Rodig, Nikhil Ramaiya and 8 more

Registry-linked trialAbstract readCase ReportsClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in The New England journal of medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00585195 (PHASE 1 SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF PF-02341066, A MET/HGFR SELECTIVE TYROSINE KINASE INHIBITOR, ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED CANCER), which is not on this map. Cited by 374 papers.

0numbers the graph read from it
0cells of the map it votes in
374citing papers in PubMed
38.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00585195 phase1completednot on this map

Phase 1 safety, pharmacokinetic and pharmacodynamic study of pf-02341066, a met/hgfr selective tyrosine kinase inhibitor, administered orally to patients with advanced cancer

TypeinterventionalSponsorPfizerRan2006 to 2022Enrolled596ConditionsNon-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell LymphomaArmsPF-02341066, Rifampin, Itraconazole
3 · Its place in the literature

Who cites it

374 citing papers in PubMed, 855 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Case Report:Frontiers in oncology · 2026
    Article
  17. Article
  18. Article
  19. Review
  20. Article

314 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 1 country.

James E ButrynskiDana-Farber Cancer Institute, Boston, MA 02115, USA.
David R D'Adamo
Jason L Hornick
Paola Dal Cin
Cristina R Antonescu
Suresh C Jhanwar
Marc Ladanyi
Marzia Capelletti
Scott J Rodig
Nikhil Ramaiya
Eunice L Kwak
Jeffrey W Clark
Keith D Wilner
James G Christensen
Pasi A Jänne
Robert G Maki
George D Demetri
Geoffrey I Shapiro
Dana-Farber Cancer Institute · USMemorial Sloan Kettering Cancer Center · USHarvard University · USMassachusetts General Hospital · USPfizer (United States) · USBrigham and Women's Hospital · US

Funding

SOFT TISSUE SARCOMA PROGRAM PROJECTP01CA047179 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI LADANYI, MARC · 1989 to 2010
$17.3M
Targeting ALK through Degradation and Allosteric InhibitorsR01CA136851 · NCI · STANFORD UNIVERSITY · PI GRAY, NATHANAEL SCHIANDER, JANNE, PASI A · 2009 to 2023
$4.6M
Translational Research Studies in Clinical Trials of Novel Therapeutics for SarcoRC2CA148260 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SCHWARTZ, GARY K · 2009 to 2010
$2.4M
NCI NIH HHS P01 CA047179NCI NIH HHS P01-CA47179NCI NIH HHS R01 CA136851NCI NIH HHS R01-CA136851NCI NIH HHS RC2 CA148260NCI NIH HHS RC2-CA148260
6 · The paper itself

Abstract

Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

Indexed as

Abdominal NeoplasmsAdultAnaplastic Lymphoma KinaseCrizotinibGranuloma, Plasma CellHumansMaleMutationNeoplasms, Muscle TissueProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-metPyrazolesPyridinesReceptor Protein-Tyrosine KinasesReceptors, Growth FactorALK protein, humanAnaplastic Lymphoma KinaseCrizotinibMET protein, humanProtein Kinase InhibitorsProtein-Tyrosine KinasesProto-Oncogene Proteins c-metPyrazolesPyridinesReceptor Protein-Tyrosine KinasesReceptors, Growth Factor

Identifiers

PMID20979472
PMCPMC3014292
OpenAlexW2172208023

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.